Monthly Intermittent Chemotherapy of Chronic Schizophrenic Outpatients with Pipothiazine Palmitate

Thirty-nine chronic schizophrenic patients were selected for a 12-month double-blind evaluation of the effectiveness of pipothiazine palmitate (PPT) and flupenthixol decanoate (FPX) in the maintenance management of their illness. Allocation was at random and, in order to allow constant injection intervals, the patients typically received every 2 weeks either 40 mg of flupenthixol decanoate or alternating injections of 100 mg of pipothiazine palmitate and placebo. At monthly intervals the patients were assessed using both a battery of rating scales (which included the Brief Psychiatric Rating Scale (BPRS), the Extrapyramidal Symptoms Rating Scale (EPS] and a general side-effects evaluation. At 3-monthly intervals they were also rated on the Comprehensive Psychiatric Rating Scale (CPRS) and the Zung Depression Scale. Haematological and biochemical tests were performed every 3 months. Both drugs provided good control of psychotic symptoms and side-effects were not troublesome. No substantial difference was detected on the CPRS and the Zung scales. There was a trend in favour of PPT on the BPRS survey, detectable at 6 months and reaching statistical significance by 12 months. We conclude that the PPT regime is at least as effective as the FPX treatment and probably more so. It is possible that even longer periods of control could be obtained with PPT.

show abstract

A Comparative Trial of Depot Pipothiazine

Steinert

Neder

Erba

et al. 1986

J Int Med Res

View full text Add to dashboard Cite

show abstract

Pipotiazine Palmitate, A Long Acting Drug, Indeed: A Case Report

Hyrman

1985

Can J Psychiatry

View full text Add to dashboard Cite

show abstract

Pipothiazine palmitate: a versatile, sustained-action neuroleptic in psychiatric practice

Schmidt

1986

Current Medical Research and Opinion

160

View full text Add to dashboard Cite

A study lasting 1 year assessed the effectiveness and tolerance of depot neuroleptic treatment with pipothiazine palmitate in 52 patients suffering from schizophrenia or related conditions (17 acute and 35 chronic). A 100 mg dose was given to 31 patients and 50 mg to 21 patients: 40 patients received injections 4-weekly, 8 patients 3-weekly and 4 patients 2-weekly. Duration of treatment ranged from 3 to 12 months, involving a total of 347 patient-months. The significant improvement produced by pipothiazine palmitate as shown by patient assessment, based on the Parkside Behaviour Rating Scale (p less than 0.05), a Hamilton-based affect scale (p less than 0.05) and a global rating scale of affect and psychomotor activity (p less than 0.01). Most target symptoms were relieved. A particularly favourable affective response was noted. The incidence of adverse reactions was low and did not present major problems; 6 cases of dystonic reaction were seen, but dealt with promptly and effectively.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Monthly Intermittent Chemotherapy of Chronic Schizophrenic Outpatients with Pipothiazine Palmitate

Abstract: Although the drug has been studied in hospitalized patients, it has yet to be tested with outpatients. This is a preliminary study

Cited by 3 publications

References 4 publications

A Comparative Trial of Depot Pipothiazine

A Comparative Trial of Depot Pipothiazine

Pipotiazine Palmitate, A Long Acting Drug, Indeed: A Case Report

Pipothiazine palmitate: a versatile, sustained-action neuroleptic in psychiatric practice

Contact Info

Product

Resources

About